Ventripoint: Uplisting To The OTCQB – The Daily Dive
Today on the Daily Dive, we are joined by George Adams, Chairman of Ventripoint Diagnostics (TSXV: VPT). George joins us this afternoon to discuss developments in the medical world related to heart transplants and the future of organ transplants, the adaptations that the medical industry continues to make related to the ongoing pandemic, a recent uplisting by Ventripoint to the OTCQB, a recent expansion to the UK market, and where the industry sits in 3D tech adoption.
Ventripoint Diagnostics has become an industry leader in the application of Artificial Intelligence to echocardiography. The company’s VMS products provide accurate volumetric cardiac measurements equivalent to an MRI. In layman terms, the company is able to accurately create a three dimensional model of a heart based on a two dimensional image produced via an echocardiogram. With the technology settled in the latest version of the product, the company has now begun selling the product to some of the world’s leading hospitals.
FULL DISCLOSURE: Ventripoint Diagnostics is a client of Canacom Group, the parent company of The Deep Dive. The company has been compensated to cover Ventripoint Diagnostics on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. We may buy or sell securities in the company at any time. Always do additional research and consult a professional before purchasing a security.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.
